Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an announcement.
Shanghai Pharmaceuticals Holding Co., Ltd. has released its first quarterly report for 2025, prepared in accordance with PRC Accounting Standards for Business Enterprises. The report, which remains unaudited, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, as affirmed by its board of directors and senior management.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and services, catering to a broad market within China.
YTD Price Performance: -14.42%
Average Trading Volume: 53,474
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.31B
For an in-depth examination of 2607 stock, go to TipRanks’ Stock Analysis page.